Latest Breaking News On - Mabel mardones - Page 1 : comparemela.com

Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

Experts discuss the impact of elacestrant on patient well-being, including potential cardiovascular and gastrointestinal toxicities, quality of life, and patient feedback regarding access to treatment.

William gradisharGregory vidalRena callahanMabel mardonesPeer exchangeEuropean society for medical oncology congressMedical oncology congressOral serdMetastatic breast cancerTherapeutic advancesPanel discussionHer positiveHer2 negativeSelective estrogen receptor degraderEndocrine therapyTargeted therapy

Elacestrant: Treatment Considerations, Including Dosing and Compliance

Experts explore treatment considerations when treating patients with metastatic breast cancer with elacestrant, including dosing, patient selection, adherence, and treatment duration. Participants also discuss dose modifications, adherence concerns, and how they determine treatment failure.

William gradisharMabel mardonesRena callahanGregory vidalPeer exchangeOral serdMetastatic breast cancerTherapeutic advancesPanel discussionHer positiveHer2 negativeSelective estrogen receptor degraderEndocrine therapyTargeted therapyTreatment developmentsMedical oncology

Greenwich LifeSciences, Inc : Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

Greenwich LifeSciences, Inc : Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

University of nebraska medical centerUnited statesBaylor universityUniversity of miamiSan franciscoSalt lake cityFeinberg schoolNew yorkSan antonioClifton parkRocky mountainNorthwestern universityPalo altoNordrhein westfalenStony brookBaylor college of medicine

Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

Experts delve into practical aspects of using elacestrant in later-line treatment of patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer, including testing for ESR1 mutations, evaluating efficacy, and monitoring for toxicity.

Rena callahanWilliam gradisharMabel mardonesGregory vidalPeer exchangeOral serdMetastatic breast cancerTherapeutic advancesPanel discussionHer positiveHer2 negativeSelective estrogen receptor degraderEndocrine therapyTargeted therapyTreatment developmentsMedical oncology

ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and discuss unmet needs in this patient population. They also describe options for mutation and resistance marker testing to guide treatment selection.

William gradisharRena callahanMabel mardonesGregory vidalPeer exchangeOral serdMetastatic breast cancerTherapeutic advancesPanel discussionHer positiveHer2 negativeSelective estrogen receptor degraderEndocrine therapyTargeted therapyTreatment developmentsMedical oncology